12,372 trials
Pulmonary Arterial Hypertension
Primary: To Assess the Pharmacokinetics (Mean AM Dose) in Subjects During Twice Daily (BID) Dosing (up to 14 Days Prior to Transitioning to Three Times Daily [TID] Dosing Regimen…
Hepatitis C Virus Infection
Primary: Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12) — 95.3; 80.7 percentage of participants — p=<0.001
Chronic HCV Infection
Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks After Discontinuation of Therapy (SVR12) — 90; 96.4; 100.0; 93.3 percentage of participants
Hemophilia A · Hemophilia B
Primary: Percentage of Bleeding Episode With "Treatment Success" — 96.19; 79.30 percent of bleeding episodes
Rheumatoid Arthritis
Primary: Number of Participants With American College of Rheumatology 20 Response at Week 24 — 36; 153 participants
Bronchial Asthma
Primary: Asthma Control Questionnaire (ACQ) Score at Baseline — 2.24; 2.15; 2.19 units on a scale
Deep Vein Thrombosis
Primary: Frequency of DVT. — 0; 2 participants — p=0.226
Chemotherapy-induced Neutropenia
Primary: Duration of Neutropenia CTCAE Grade 4 — 0.905; 0.791; 1.725 days
Human Epithelial Receptor (HER)-2 Positive Breast Cancer
Primary: Overall Response Rate — 56; 48 Participants
Ovarian Cancer · Fallopian Tube Cancer · Peritoneal Cancer
Primary: Postoperative Length of Hospital Stay — 4.4; 4.3 days — p=0.34
Non-small Cell Lung Cancer
Primary: Overall Response Rate — 34.63; 33.82 percentage of participans
Meniere's Disease
Primary: Vertigo Attacks — 16.4; 19.93; 1.6; 2.5 Vertigo Attacks — p=0.271
Psoriasis
Primary: Time to at Least a 1 Point Improvement on the Patient's Global Assessment of Disease Severity (PatGA) Score — 5.0; 6.0 Days
Psoriasis
Primary: Number of Participants Achieving a Static Physician Global Assessment (sPGA) of (0, 1) (Efficacy of Ixekizumab in Participants With Moderate to Severe Chronic Plaque…
Hepatitis C Virus · HIV
Primary: Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12) — 96.1 percentage of participants